Tadao Ishida - Publications

Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 15, 2026

Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group.

Journal: Clinical hematology international

Published: March 31, 2026

Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.

Journal: British journal of haematology

Published: January 28, 2026

Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.

Journal: Transplantation and cellular therapy

Published: January 19, 2026

Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives.

Journal: Cells

Published: January 08, 2026

Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: January 06, 2026

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre-BCMA Era: A Prospective, Single-Centre Study.

Journal: EJHaem

Published: January 03, 2026

Dual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab.

Journal: The New England journal of medicine

Published: December 08, 2025

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Journal: Cells

Published: December 02, 2025

Ciltacabtagene Autoleucel Versus Idecabtagene Vicleucel in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma with 2-4 Prior Lines of Therapy: Updated Matching-Adjusted Indirect Comparison.

Journal: Advances in therapy

Published: October 03, 2025

Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.

Journal: International journal of hematology

Published: September 27, 2025

Successful management of cardiac arrest due to cytokine release syndrome following chimeric antigen receptor T-cell therapy for multiple myeloma

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: September 03, 2025